Prohibitin ligands in cell death and survival: mode of action and therapeutic potential.
Fiche publication
Date publication
mars 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent, Dr NEBIGIL-DESAUBRY Canan
Tous les auteurs :
Thuaud F, Ribeiro N, Nebigil CG, Desaubry L
Lien Pubmed
Résumé
Prohibitins (PHBs) are scaffold proteins that modulate many signaling pathways controlling cell survival, metabolism, and inflammation. Several drugs that target PHBs have been identified and evaluated for various clinical applications. Preclinical and clinical studies indicate that these PHB ligands may be useful in oncology, cardiology, and neurology, as well as against obesity. This review covers the physiological role of PHBs in health and diseases and current developments concerning PHB ligands.
Référence
Chem Biol. 2013 Mar 21;20(3):316-31